Determinants of Enteric Calicivirus Infection.

肠道杯状病毒感染的决定因素。

基本信息

  • 批准号:
    10213588
  • 负责人:
  • 金额:
    $ 37.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Human norovirus (HuNoV) gastroenteritis is a significant public health burden worldwide. The lack of a robust and reproducible HuNoV cell culture system still limits our ability to study fundamental aspects of HuNoV infection. While several recent breakthroughs increased our ability to propagate HuNoVs in vitro (e.g. B cell and human enteroid cultures), these systems are not robust enough, can be time consuming and expensive or hard to replicate. The surrogate models available for HuNoV research do not necessarily reflect essential biological features of HuNoVs and their natural host. In this proposal we will use our novel rhesus enteric caliciviruses (ReCV) model that reflects the biological features and diversity of HuNoVs to identify host determinants of infection. Zoonotic/interspecies transmission of ReCVs and HuNoVs between human and non- human primate hosts suggests evolutionary conservation of shared factors of host susceptibility between the two genera. Here we seek to identify host determinants of enteric calicivirus infection using CRISPR-Cas9 genome wide screening. We recently identified a functional ReCV entry receptor that is necessary for ReCV permissiveness in cell culture. We hypothesize that the ReCV entry receptor is also involved in HuNoV infections. This hypothesis will be tested in the following specific aims. Aim 1. Characterize receptor mediated ReCV infection. Aim 2: Comparative characterization of HuNoV and ReCV infections in enteroid and B cell cultures. In the first aim we will dissect the role of HBGAs in ReCV receptor mediated entry by using ReCV isolates with disctinct HBGA binding, cell lines expressing different HBGAs and/or the receptor, Enterobacter SENG-6 EPS and different synthetic HBGAs. We will also evaluate the role of the different transmembrane isoforms of the receptor in infection and map the ReCV interaction site and importance of glycosylation. In the second aim, we will evaluate the role of ReCV entry receptor in HuNoV infections in enteroid and B cell cultures and identify other cell surface components playing a role in HuNoV infections. We will also evaluate the mechanism of bile or bile salts in promoting HuNoV infections and the role of M cells in infections of polarized cells. Our long-term goal is to identify and characterize viral and host determinants of ReCV and HuNoV infections and to develop novel intervention/prevention strategies. Our proposal uses a novel enteric calicivirus model to understand viral entry and the role of bile and HBGAs in enteric viral infections. Our findings with ReCVs may be directly transferable to HuNoV infection. The major significance of this project is the identification of determinants of susceptibility to enteric calicivirus infection that can lead to improved HuNoV cell culture systems and new intervention/prevention strategies.
项目摘要 人类诺如病毒(HuNoV)胃肠炎是全球范围内的重大公共卫生负担。缺乏一个强大的 可重复的HuNoV细胞培养系统仍然限制了我们研究HuNoV基本方面的能力 感染虽然最近的几个突破增加了我们在体外增殖HuNoV(例如B细胞)的能力 和人肠类培养物),这些系统不够稳健,可能是耗时和昂贵的,或者 很难复制。可用于HuNoV研究的替代模型不一定反映基本的 HuNoV及其天然宿主的生物学特征。在这项提案中,我们将使用我们的新恒河猴肠 杯状病毒(ReCV)模型,反映了HuNoV的生物学特征和多样性,以识别宿主 感染的决定因素。ReCV和HuNoV在人与非人之间的动物源性/种间传播 人类灵长类宿主表明,在进化过程中, 两个属。在这里,我们试图使用CRISPR-Cas9鉴定肠道杯状病毒感染的宿主决定因素。 全基因组筛选我们最近发现了一种功能性ReCV进入受体, 在细胞培养中的宽容。我们假设ReCV进入受体也参与了HuNoV 感染.这一假设将在以下具体目标中得到检验。目标1。表征受体介导 ReCV感染。目的2:肠道和B细胞中HuNoV和ReCV感染的比较特征 cultures.在第一个目标中,我们将通过使用ReCV来剖析HBGAs在ReCV受体介导的进入中的作用。 具有不同HBGA结合的分离株,表达不同HBGA和/或受体的细胞系,肠杆菌属 SENG-6 EPS和不同的合成HBGA。我们还将评估不同跨膜蛋白的作用。 研究感染中受体的亚型,并绘制ReCV相互作用位点和糖基化的重要性。在 第二个目的是研究ReCV进入受体在HuNoV感染肠道和B细胞中的作用 培养和鉴定在HuNoV感染中起作用的其他细胞表面组分。我们还将评估 胆汁或胆汁盐促进HuNoV感染的机制以及M细胞在感染中的作用。 极化细胞我们的长期目标是鉴定和表征ReCV的病毒和宿主决定因素, HuNoV感染,并开发新的干预/预防策略。我们的建议使用一种新型的肠溶 杯状病毒模型,以了解病毒进入以及胆汁和HBGAs在肠道病毒感染中的作用。我们 ReCV的发现可能直接转移到HuNoV感染。本项目的主要意义在于 确定肠道杯状病毒感染易感性的决定因素, HuNoV细胞培养系统和新的干预/预防策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIBOR FARKAS其他文献

TIBOR FARKAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIBOR FARKAS', 18)}}的其他基金

Determinants of Enteric Calicivirus Infection.
肠道杯状病毒感染的决定因素。
  • 批准号:
    10317228
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:
Determinants of Enteric Calicivirus Infection.
肠道杯状病毒感染的决定因素。
  • 批准号:
    9810867
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:
Determinants of Enteric Calicivirus Infection.
肠道杯状病毒感染的决定因素。
  • 批准号:
    10442726
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了